In a transformative breakthrough, a newly developed DNA test has the potential to spare millions of breast cancer patients from the harsh realities of chemotherapy, according to findings from a robust international study. Conducted among over 4,000 newly diagnosed patients across several countries, the research underscores an urgent re-evaluation of treatment protocols, promising not only to enhance patient experience but also to tailor cancer care more effectively.
The study, spearheaded by researchers at University College London (UCL), reveals that more than two-thirds of participants could safely forgo chemotherapy in favor of hormone therapy alone. This is particularly significant given chemotherapy's notorious side effects, which include fatigue, nausea, hair loss, and potential fertility issues. The innovation comes as a beacon of hope for a demographic long beleaguered by the rigors of treatment.
By utilizing a gene test known as Prosigna, scientists measured the activity of 50 genes linked to breast cancer growth to ascertain the likelihood of cancer recurrence. Remarkably, the results indicated that those receiving a low-risk score—approximately two-thirds of the cohort— registered a five-year survival rate of 93.7%. This outcome stands closely alongside the 94.9% survival rate seen in patients who did undergo chemotherapy, suggesting that the treatment may be more superfluous than previously thought.
The standard approach for breast cancer treatment typically starts with surgery to excise tumors, followed by chemotherapy aimed at reducing the chances of recurrence. However, researchers at UCL have expressed concerns that chemotherapy often provides minimal advantages for patients with the most prevalent form of breast cancer, a sentiment echoed in clinical data looking at the treatment's efficacy.
Empowering findings from this study could mean that as many as 5,000 National Health Service (NHS) patients annually in the UK might entirely evade chemotherapy. Karen Bonham, a Cardiff resident and trial participant, spoke to the emotional weight of the results, describing her relief as an “immense joy” akin to Christmas. Having dodged chemotherapy thanks to the Prosigna test, Bonham has pursued radiotherapy and hormone therapy over the past eight years.
“Cancer diagnosis and treatment can be shocking,” she shared. “You are thrust into a realm of uncertainty. Life priorities shift dramatically—you just want to survive.”
These groundbreaking findings will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, marking a pivotal moment in cancer research. Professor David Miles, a leading cancer specialist involved in the study, hailed the revelations as “practice-changing.”
“We can now confidently predict that many patients will gain no benefit from chemotherapy, thus sparing them from unnecessary treatment,” he explained to BBC's Newshour. “This test offers the possibility of clearly determining which women will not benefit and should not endure the associated side effects.”
The illumination brought to the field by the Prosigna test has already caught the attention of many within the cancer community. Tanya Hutson, a breast cancer survivor who underwent chemotherapy in 2022, extolled the emergence of the DNA test as “absolutely amazing.” She noted the “brutal” experience of chemotherapy, stressing the implications for patients who need not endure the treatment. “This is a game changer for those who don't need it but are still receiving it.”
As promising as these revelations appear, researchers caution that the findings' applicability to individuals under the age of 40 remains to be determined, with clarity still several years away.
Source: BBC Health
